These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9295 related articles for article (PubMed ID: 123336)

  • 1. Correlated suppression by 5-bromodeoxyuridine of tumorigenicity and plasminogen activator in mouse melanoma cells.
    Christman JK; Silagi S; Newcomb EW; Silverstein SC; Acs G
    Proc Natl Acad Sci U S A; 1975 Jan; 72(1):47-50. PubMed ID: 123336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-cultivation of tumorigenic mouse melanoma cells with cells of a non-tumorigenic subclone inhibits plasminogen activator expression by the melanoma cells.
    Kyner D; Christman J; Acs G; Silagi S; Newcomb EW; Silverstein SC
    J Cell Physiol; 1978 May; 95(2):159-67. PubMed ID: 206566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of melanoma cell tyrosinase activity and tumorigenicity after incorporation of bromouracil for one or two cell divisions.
    Wrathall JR; Newcomb EW; Balint R; Zeitz L; Silagi S
    J Cell Physiol; 1975 Dec; 86 Suppl 2(3 Pt 2):581-92. PubMed ID: 811676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant mouse melanoma cells do not form tumors when mixed with cells of a non-malignant subclone: relationships between plasminogen activator expression by the tumor cells and the host's immune response.
    Newcomb EW; Silverstein SC; Silagi S
    J Cell Physiol; 1978 May; 95(2):169-77. PubMed ID: 306389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible suppression of malignancy and differentiation of melanoma cells.
    Silagi S
    Am J Pathol; 1977 Dec; 89(3):671-84. PubMed ID: 596422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects on growth and tumorigenicity of mouse melanoma cells by thymidine and its analogs, 5-ethyl- and 5-bromodeoxyuridine.
    Silagi S; Balint RF; Gauri KK
    Cancer Res; 1977 Sep; 37(9):3367-73. PubMed ID: 884681
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of thymidine analogs on tyrosinase activity and mRNA accumulation in mouse melanoma cells.
    Kidson SH; De Haan JB
    Exp Cell Res; 1990 May; 188(1):36-41. PubMed ID: 2139417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation of plasminogen activator from the transformed phenotype in a 5-bromodeoxyuridine dependent mutant of Syrian hamster melanoma cells.
    Rosenthal SL; Zucker D; Davidson RL
    J Cell Physiol; 1978 Jun; 95(3):275-85. PubMed ID: 649664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 5-bromodeoxyuridine on tumorigenicity, immunogenicity, virus production, plasminogen activator, and melanogenesis of mouse melanoma cells.
    Silagi S
    Int Rev Cytol; 1976; 45():65-111. PubMed ID: 821894
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumorigenicity, immunogenicity, and virus production in mouse melanoma cells treated with 5-bromodeoxyuridine.
    Silagi S; Beju D; Wrathall J; Deharven E
    Proc Natl Acad Sci U S A; 1972 Nov; 69(11):3443-7. PubMed ID: 4343973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of malignancy and differentiation in melanotic melanoma cells.
    Silagi S; Bruce SA
    Proc Natl Acad Sci U S A; 1970 May; 66(1):72-8. PubMed ID: 4921328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells.
    Collen D; Billiau A; Edy J; De Somer P
    Biochim Biophys Acta; 1977 Sep; 499(2):194-201. PubMed ID: 198009
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship of antigenicity of melanoma cells grown in 5-bromodeoxyuridine to reduced tumorigenicity.
    Silagi S; Newcomb EW; Weksler ME
    Cancer Res; 1974 Jan; 34(1):100-4. PubMed ID: 4358536
    [No Abstract]   [Full Text] [Related]  

  • 14. Bromodeoxyuridine dependence--a new mutation in mammalian cells.
    Davidson RL; Bick MD
    Proc Natl Acad Sci U S A; 1973 Jan; 70(1):138-42. PubMed ID: 4509645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The suppression of tumorigenicity in human X mouse cell hybrids. II. The relationship between tumorigenicity and parameters of transformation in vitro.
    Chopan M; Kopelovich L
    Exp Cell Biol; 1981; 49(3):132-40. PubMed ID: 7195844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of 5-bromodeoxyuridine on messenger RNA production in cultured cells.
    Price PM
    Biochim Biophys Acta; 1976 Oct; 447(3):304-11. PubMed ID: 987803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolysis associated with oncogenic transformation. Requirement of plasminogen for correlated changes in cellular morphology, colony formation in agar, and cell migration.
    Ossowski L; Quigley JP; Kellerman GM; Reich E
    J Exp Med; 1973 Nov; 138(5):1056-64. PubMed ID: 4355423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathology and host response associated with reduced tumorigenicity of 5-bromodeoxyuridine--treated murine melanoma cells.
    Gyi KK; Wrathall JR
    Am J Pathol; 1983 Feb; 110(2):135-47. PubMed ID: 6824061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.
    Stack MS; Gately S; Bafetti LM; Enghild JJ; Soff GA
    Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):77-84. PubMed ID: 10229661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator production accompanies loss of anchorage regulation in transformation of primary rat embryo cells by simian virus 40.
    Pollack R; Risser R; Conlon S; Rifkin D
    Proc Natl Acad Sci U S A; 1974 Dec; 71(12):4792-6. PubMed ID: 4373730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 465.